Hyung Joo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyung Joo Lee has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
- Adam Spruce
Cancer Research Horizons, Cancer Research UK, Cambridge, United Kingdom
17 shared publications - Barrett R. B. Nuttall
Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts
17 shared publications - Cath Eberlein
AstraZeneca 1 Small Molecule Bioscience, Oncology Targeted Discovery, Oncology R&D Cambridge, United Kingdom
17 shared publications - Chang Kim
AstraZeneca 5 Discovery Sciences Cambridge, United Kingdom
17 shared publications - Daniel Barrell
AstraZeneca 8 Oncology R&D Cambridge, United Kingdom
17 shared publications - David Esopi
AstraZeneca 2 Small Molecule Bioscience, Oncology Targeted Discovery, Oncology R&D Waltham, Massachusetts
17 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
List of names and affiliations for individuals associated with the Functional Gemonics Centre FGC.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
List of names and affiliations for individuals associated with the Functional Gemonics Centre FGC.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Extended analysis of epigenomic landscape in ER+ breast cancer cells treated with capivasertib.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Extended analysis of epigenomic landscape in ER+ breast cancer cells treated with capivasertib.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Capivasertib sensitizers are enriched for members of epigenetic regulator families.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Capivasertib sensitizers are enriched for members of epigenetic regulator families.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Characterisation and validation of Cas9-expressing ER+ breast cancer cell and quality assessment of the CRISPR screening data.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Characterisation and validation of Cas9-expressing ER+ breast cancer cell and quality assessment of the CRISPR screening data.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Capivasertib resistant cells characterization.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Capivasertib resistant cells characterization.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
KDM5C and KAT6A KO increases effectiveness of capivasertib.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
KDM5C and KAT6A KO increases effectiveness of capivasertib.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
KDM5 and KAT6A/Bi sensitize ER+BC cells to AKT inhibition.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
KDM5 and KAT6A/Bi sensitize ER+BC cells to AKT inhibition.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Inhibition of KDM5 and KAT6A/B with small molecules restores capivasertib response in resistant ER+ breast cancer cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Inhibition of KDM5 and KAT6A/B with small molecules restores capivasertib response in resistant ER+ breast cancer cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Gene expression changes following KDM5C a in combination with capivasertib.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Gene expression changes following KDM5C a in combination with capivasertib.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Effects on pathway biomarker responses following treatment of KDM5C and KAT6A KO cells with capivasertib and fulvestrant and the combination.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer
Effects on pathway biomarker responses following treatment of KDM5C and KAT6A KO cells with capivasertib and fulvestrant and the combination.